MazharA., JohnsonR., GillenD., StivelmanJ., RyanM., DavisC.Risk factors and mortality associated with calciphylaxis in end-stage renal disease.Kidney Int2001; 60: 324–32.
2.
FineA., ZachariasJ.Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy.Kidney Int2002; 61: 2210–17.
3.
MunarM., AlarcónA., BernabéuR., MoreyA., GascóJ., LosadaP.[Report of a case with skin lesions and calciphylaxis.] [In Spanish]Nefrología2001; 21: 501–4.
WilmerW.A., MagroC.M.Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment.Semin Dial2002; 15: 172–86.
6.
MussoC.G., GuelmanR., VarelaF., PidouxR., SchreckC., RosaDiezG.Ibandronate improves hyperphosphatemia in dialysis patients with hyperparathyroidism.Int Urol Nephrol2004; 36: 625–7.
7.
MonneyP., NguyenQ., PerroudH., DescombesE.Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure.Nephrol Dial Transplant2004; 19: 2130–2.
